A non-clinical comparative study of IL-23 antibodies in psoriasis

• Main Authors: Li Zhou (Author), Yibing Wang (Author), Qi Wan (Author), Fei Wu (Author), Jeffrey Barbon (Author), Robert Dunstan (Author), Stephen Gauld (Author), Mark Konrad (Author), Laura Leys (Author), Richard McCarthy (Author), Marian Namovic (Author), Christine Nelson (Author), Gary Overmeyer (Author), Denise Perron (Author), Zhi Su (Author), Leyu Wang (Author), Susan Westmoreland (Author), Jun Zhang (Author), Rui Zhu (Author), Geertruida Veldman (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability, IL-23 binding affinity, inhibitory-binding mode...